Analysis: Heart device troubles cloud St Jude’s outlook

CHICAGO (Reuters) – Twin setbacks for St Jude Medical Inc’s heart rhythm devices are raising concerns on Wall Street that doctors will curb use of the company’s products, weakening its position in the $6.5 billion global market for implantable defibrillators. Early last week, St Jude halted sales of its QuickSite and QuickFlex leads, wires that carry electricity from defibrillators to the heart, due to concerns the insulation could wear away and expose the wires. …